PARIS, France I January 9, 2025 I Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an ...

LONDON, UK & SAN FRANCISCO, CA, USA I January 09, 2025 I Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage ...

PALO ALTO, CA and NEEDHAM, MA, USA and MELBOURNE, Australia I January 08, 2025 I Bitterroot Bio, a leader in developing innovative medicines in the field of ...

Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...

NEW YORK, NY, USA I January 07, 2025 I Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

The Company has aligned on clinical plan based on a positive FDA meeting, leveraging clinical data from a first-in-human Phase 1 trial published today in ...

New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 ...

BEIJING, China & ALAMEDA, CA, China & TAIPEI, Taiwan I January 07, 2025 I Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a ...

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo ...

SAN DIEGO, CA, USA & SHANGHAI, China I January 06, 2024 I Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming ...

ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...